CogNano

Kyoto, Japan· Est. 2014

CogNano uses alpaca-derived VHH antibodies and AI to discover novel biomarkers and drug targets for unmet medical needs in oncology.

cognano.co.jp

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

Private Company

Funding information not available

AI Company Overview

CogNano uses alpaca-derived VHH antibodies and AI to discover novel biomarkers and drug targets for unmet medical needs in oncology.

OncologyInfectious Diseases

Technology Platform

IBMET (Inverse Biomarker Exploring Technology): A platform that uses massive VHH antibody-antigen pair datasets from in-house alpaca/shark immunization and next-generation sequencing, combined with AI/LLMs, to discover novel disease targets.

Opportunities

Opportunities include leveraging its unique dataset to become a leader in novel target discovery for 'undruggable' cancers, expanding into other disease areas with unknown biomarkers, and forming lucrative partnerships with large pharma companies seeking to de-risk early-stage R&D.

Risk Factors

Key risks include the high technical risk of validating novel, computationally discovered targets in humans, the capital-intensive nature of maintaining animal colonies and AI infrastructure, and competition from other AI/biotech platforms with more advanced clinical pipelines.

Competitive Landscape

Competes with nanobody therapeutics companies (e.g., Sanofi/Ablynx, AdAlta) and AI drug discovery platforms. Differentiation lies in its proprietary inverse discovery approach and ownership of a massive, high-quality VHH antibody dataset generated from its unique in-house animal immunology platform.

More companies in Japan →